This is the authors' abstract. We don't add key points for this paper.
The United States Food and Drug Administration has approved five MEK inhibitor (MEKi) agents trametinib, selumetinib, mirdametinib, binimetinib, and cobimetinib for various oncologic conditions. Increasingly, children are receiving MEKi treatment for childhood malignancies, yet their risk of MEKi-related ocular adverse events (OAE) is not well understood.1-3
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Avery et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: